Clinical Data and Roche Sign Co-Marketing Agreement Relating to Cogenics Division Acquisition of 454 GS FLX Sequencing System.

NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ: CLDA) and Roche Diagnostics today signed a co-marketing agreement in support of the installation by the Cogenics Division of Clinical Data, the worldwide leading pharmacogenomics and molecular biology services company, of a 454 Genome Sequencer FLX System in one of their European facilities. Cogenics plans to offer the 454 GS FLX 'Next Generation' sequencing technology as a fee-for-service offering to clients worldwide, with applications ranging from whole genome sequencing to genome wide expression profiling, and will collaborate with Roche to co-market the service.

"The Genome Sequencer FLX represents the most advanced state-of-the-art, high throughput and cost-effective sequencing technology to support the expectations and needs of our customers' research," stated Robert Bondaryk, Ph.D., Senior Vice President and General Manager of Cogenics. "With our proven track record of offering sequencing services in both research and regulated environments, this next generation platform will give us increased sales opportunities and accelerate revenue growth across the broad array of molecular biology services that Cogenics offers. We look forward to our collaboration with Roche to present a new generation of sequencing solutions to genomics researchers globally."

"We are pleased to offer our customers access to the 454 GS FLX platform supported by our recognized experience and expertise in genomics and pharmacogenomics," said Paul Tomlin, Cogenics Director of European Operations. "As a partner of major genomic projects such as the sequencing of the Tomato Genome within the Solanacea Genome Network and several large re-sequencing projects for SNPs discovery and gene profiling studies, Cogenics has already established itself as a worldwide leader in this field. Now we intend to consolidate this position through the installation of cutting edge platforms like the 454 GS FLX together with the co-marketing agreement with Roche."

"We are glad to welcome Clinical Data in the fast growing family of Genome Sequencer users. Clinical Data's Cogenics Division is a well-known company in the sequencing world, and we regard their decision as a recommendation to use our technology," said Manfred Baier, Head of Roche Applied Science in Penzberg/Germany.

About Roche and the Roche Diagnostics Division

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2005, sales by the Pharmaceuticals Division totaled 27.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.2 billion Swiss francs. Roche employs roughly 70,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our websites www.roche.com and www.roche-diagnostics.com

About Cogenics

Cogenics offers more than 17 years of experience as a trusted provider of the broadest range of pharmacogenomics and molecular biology services available globally. Cogenics provides integrated services for nucleic acid extraction, genotyping, sequencing, QPCR, and gene expression, as well as serving as a biorepository, for both research and regulated environments: GLP, cGMP and CLIA. Cogenics combines operations from the acquisitions of Genaissance Pharmaceuticals, Lark Technologies (US & UK), Icoria, and Genome Express (France). Its customers include some of the world's most respected pharmaceutical and biotechnology companies, agencies of the US National Institutes of Health, leading government and academic researchers in the international life science community, and major agricultural companies and agencies.

About Clinical Data, Inc.

Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, from targeted science to better healthcare. Its Cogenics division provides molecular biology and pharmacogenomics services to pharmaceutical and biotech companies and academics institutions in both research and regulated environments. Its PGxHealth division focuses on genetic test and biomarker development to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Vital Diagnostics division offers in vitro diagnostics solutions for the clinical laboratory. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists, and health plans worldwide.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to statements regarding: our ability to successfully integrate the operations, business, technology and intellectual property obtained in our acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety; our ability to achieve the expected synergies and operating efficiencies from all of our acquisitions; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for pharmacogenetic and biomarker products and services; general economic downturns; and other risks contained in our various SEC reports and filings, including but not limited to our Quarterly Report on Form 10-Q for the quarter ended December 31, 2006, filed with the SEC on February 14, 2007, and our Current Reports on Form 8-K filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Internet Website: www.clda.com